Moxibustion as an adjunctive treatment for rheumatoid arthritis and its effects on the serum levels of SOST and β-catenin.
10.13703/j.0255-2930.20230414-k0005
- Author:
Si-Yu TAO
1
;
Jie TANG
2
;
Xue WANG
2
;
Nan-Nan JIANG
2
;
Yuan LI
3
;
Ping WU
4
Author Information
1. College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China. 269402733@qq.com.
2. College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
3. Department of Rheumatic Immunology, Hospital of Chengdu University of TCM/TCM Hospital of Sichuan Province.
4. College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China. wuping_33@163.com.
- Publication Type:Journal Article
- Keywords:
Wnt/β-catenin signaling pathway;
bone metabolism;
moxibustion;
rheumatoid arthritis (RA);
sclerostin (SOST);
tumor necrosis factor-α (TNF-α);
β-catenin
- MeSH:
Humans;
Moxibustion;
Tumor Necrosis Factor-alpha;
beta Catenin;
Acupuncture Points;
Arthritis, Rheumatoid/therapy*;
Arthralgia;
Adaptor Proteins, Signal Transducing
- From:
Chinese Acupuncture & Moxibustion
2023;43(12):1384-1389
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To observe the clinical efficacy of moxibustion as an adjunctive treatment for rheumatoid arthritis (RA) based on conventional medication and its effects on serum sclerostin (SOST) and β-catenin levels, exploring the potential mechanisms by which moxibustion may protect joint bones in RA patients.
METHODS:Seventy-six RA patients were randomly divided into an observation group (38 cases, 3 cases dropped out) and a control group (38 cases, 4 cases were eliminated, 2 cases dropped out). The patients in the control group were treated with conventional oral medication; based on the treatment of the control group, the patients in the observation group were treated with moxibustion. The direct moxibustion was applied at Zusanli (ST 36) on both sides and ashi points around small joints, and indirect moxibustion was applied at Shenshu (BL 23) on both sides and ashi points around large joints. The treatment was given three times a week for a total of 5 weeks. The count of pain and swollen joint, morning stiffness score, disease activity score of 28 joints (DAS28), visual analogue scale (VAS) score, health assessment questionnaire (HAQ) score, and serum levels of SOST, β-catenin, and tumor necrosis factor-α (TNF-α) were evaluated before and after treatment in the two groups.
RESULTS:Compared those before treatment, after treatment, both groups showed a reduction in pain and swollen joint count (P<0.01, P<0.05), morning stiffness, DAS28, VAS, and HAQ scores (P<0.01, P<0.05), with the observation group having lower scores than the control group (P<0.01). Serum levels of SOST, β-catenin, and TNF-α after treatment in the observation group were lower than those in both before treatment and the control group (P<0.01, P<0.05). There was a positive correlation between the difference in serum β-catenin levels before and after treatment and the difference in serum SOST (r=0.578, P<0.001) and TNF-α (r=0.403, P<0.05) levels in the observation group.
CONCLUSIONS:In addition to medication, moxibustion as an adjunctive treatment could significantly alleviate joint pain and reduce disease activity in RA patients, suggesting a potential role in joint protection. This mechanism may be related to the inhibition of the inflammatory factor TNF-α, regulation of β-catenin levels, and reduction in the production of the endogenous negative regulator protein SOST within the Wnt/β-catenin signaling pathway.
